Contact us
Microscopic view of bone marrow showing clusters of purple blood cells, pink-stained tissue, and several large white fat cells scattered throughout the sample.

Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain

Authors: J-Á Hernández-Rivas, M Arnao, J M A Pérez, A Rubio, E G García, D de Miguel, D Cherepanov, D Romanus, K Verleger, C Johnson, S L Corman, M Grande, E P Persona

Published: Future Oncology, 2021

View publication

Aim

To describe treatment patterns and outcomes in nontransplant newly diagnosed multiple myeloma (NDMM) patients in Spain.

Methods

This retrospective study included two cohorts of NDMM patients diagnosed between 1 January 2012 to 31 December 2013 and 1 April 2016 to 31 March 2017.

Results

Among 113 patients, proteasome inhibitor (PI) + alkylator combinations (49%) and PI-based regimens without an alkylator (30%) were the most common first-line (1L) therapies. Use of PI + immunomodulatory drug-based regimens increased between the cohorts; PI-based regimens without an alkylator/immunomodulatory drug decreased. Use of 1L oral regimens was low but increased over time; use of maintenance therapy was low across both periods. Median 1L duration of treatment was 6.9 months. 

Conclusion

Short 1L duration of treatment and low use of 1L oral regimens and maintenance therapy highlight unmet needs in NDMM.